NMRD (NMRD)
Nemaura Medical Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 975 |
| Oct 19, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 301 |
| Oct 6, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 1,166 |
| Oct 1, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 3,700 |
| Sep 30, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 227 |
| Sep 29, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 1,003 |
Nemaura Medical Inc. is a medical technology company dedicated to inventing, developing, and bringing to market diagnostic medical devices.
Its flagship product, sugarBEAT, is an innovative, non-invasive continuous glucose monitoring (CGM) system. This device is designed to assist individuals with Type 1 and Type 2 diabetes in managing their condition, and it can also screen for pre-diabetic states. Beyond this, Nemaura offers proBEAT, a wellness guidance service that delivers educational prompts to users about factors influencing their blood sugar profiles.
The company also conducts specialized programs aimed at diabetes prevention and reversal. Established in 2009, Nemaura Medical Inc. operates from its headquarters in New York City.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US30d Avg
638
60d Avg
1.25K
90d Avg
2.05K